Polypharmacy, chronic kidney disease, and benign prostatic hyperplasia in patients with chronic obstructive pulmonary disease newly treated with long-acting anticholinergics
- 1 November 2017
- journal article
- Published by Elsevier in Respiratory Medicine
- Vol. 132, 195-202
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
This publication has 26 references indexed in Scilit:
- The ‘real-life’ COPD patient in Germany: The DACCORD studyRespiratory Medicine, 2016
- Global and regional estimates of COPD prevalence: Systematic review and meta–analysisJournal of Global Health, 2015
- Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary diseaseInternational Journal of Chronic Obstructive Pulmonary Disease, 2015
- Chronic obstructive pulmonary disease in primary care: an epidemiologic cohort study from the Canadian Primary Care Sentinel Surveillance NetworkCMAJ Open, 2015
- Comorbidity and health-related quality of life in patients with severe chronic obstructive pulmonary disease attending Swedish secondary care unitsInternational Journal of Chronic Obstructive Pulmonary Disease, 2015
- The distribution of COPD in UK general practice using the new GOLD classificationEuropean Respiratory Journal, 2013
- Comorbidity in patients with chronic obstructive pulmonary disease in family practice: a cross sectional studyBMC Family Practice, 2013
- Comorbidities, Patient Knowledge, and Disease Management in a National Sample of Patients with COPDThe American Journal of Medicine, 2009
- Characteristics of chronic obstructive pulmonary disease in Spain from a gender perspectiveBMC Pulmonary Medicine, 2009
- Diagnostic certainty, co-morbidity and medication in a primary care population with presumed airway obstruction: the DIDASCO2 studyPrimary Care Respiratory Journal, 2008